Circle8 Group (CIRC) vs Harvard Bioscience (HBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Harvard Bioscience (HBIO) has outperformed Circle8 Group (CIRC) over the past year, gaining 37.5% versus a loss of 94.4%. Over five years, HBIO leads with a -87.4% price change compared with -99.9% for CIRC. Harvard Bioscience is the larger company by market cap ($39.6 million vs $16.0 million), about 2.5 times the size, while Circle8 Group is growing revenue faster (-1.5% vs -8.1%).
Circle8 Group converts more of its revenue into profit, with a net margin of -13.6% versus -65.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CIRC | HBIO |
|---|---|---|
| Share price | $0.1361 | $8.66 |
| Market cap | $15.99M | $39.60M |
| 1-day change | -12.25% | -0.23% |
| YTD return | -89.77% | +29.25% |
| 1-year return | -94.44% | +37.46% |
| 5-year return | -99.88% | -87.45% |
| Forward P/E | — | 16.34 |
| EPS (TTM) | $-2.14 | $-2.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $435.88M | $86.55M |
| Revenue growth (YoY) | -1.52% | -8.06% |
| Net income (latest FY) | $-59.43M | $-56.70M |
| Gross margin | 10.55% | 57.67% |
| Operating margin | -11.52% | -56.13% |
| Net margin | -13.63% | -65.51% |
| 52-week high | $4.56 | $10.20 |
| 52-week low | $0.136 | $4.00 |
| Distance from 52-week high | -97.02% | -15.10% |
| Analyst consensus | — | none |
| Avg. price target upside | — | -13.39% |
| Average volume | 1.13M | 21.82K |
| Shares outstanding | 117.49M | 4.57M |
| Employees | 300 | 316 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Harvard Bioscience is about 2.5 times larger than Circle8 Group by market value ($39.60M vs $15.99M).
- HBIO has outperformed CIRC by 131.9 percentage points over the past year.
- Circle8 Group is more profitable, keeping -13.6 cents of every revenue dollar as net income versus -65.5 cents for Harvard Bioscience.
- Circle8 Group grew revenue faster in its latest fiscal year (-1.52% vs -8.06%).
About Circle8 Group
CIRC stock →Circle8 Group, Inc. provides talent management services.
Industrials · Biotechnology: Laboratory Analytical Instruments · 300 employees
About Harvard Bioscience
HBIO stock →Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally.
Industrials · Biotechnology: Laboratory Analytical Instruments · 316 employees
CIRC vs HBIO FAQ
Which is bigger, Circle8 Group or Harvard Bioscience?
Harvard Bioscience (HBIO) is larger, with a market capitalization of $39.60M compared with $15.99M for Circle8 Group (CIRC).
Which stock has performed better over the past year, CIRC or HBIO?
HBIO returned +37.46% over the past 12 months, compared with -94.44% for CIRC (price return, excluding dividends). Past performance does not predict future results.
Are Circle8 Group and Harvard Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.